

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Novo Nordisk (Denecimig [Mim8]) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> Gene People Genetic Alliance UK Haemophilia Society Immunodeficiency UK South Asian Health Foundation Specialised Healthcare Alliance <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> Association of Genetic Nurses & Counsellors British Blood Transfusion Society British Geriatrics Society British Paediatric Allergy, Immunity and Infection Group British Society for Genetic Medicine British Society for Haematology Haemophilia Chartered Physiotherapists Association Haemophilia Nurses Association Neonatal and Paediatric Pharmacists Group Royal College of General Practitioners Royal College of Nursing Royal College of Paediatrics & Child Health Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Forum on Haemoglobin Disorders 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Haemophilia Northern Ireland Haemophilia Scotland Haemophilia Wales Healthcare Improvement Scotland Hospital Information Services - Jehovah's Witnesses Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation NHS Wales Joint Commissioning Committee Scottish Medicines Consortium Welsh Government <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> Bio Products Laboratory (factor VIII) CSL Behring UK (factor VIII) Grifols UK (factor VIII) Novo Nordisk (factor VIII: eptacog alfa, turoctocog alfa pegol) Octopharma (factor VIII: simoctocog alfa) Pfizer (factor VIII: moroctocog alfa) Roche (emicizumab)

Final stakeholder list for the evaluation of denecimig (Mim8) for preventing bleeding episodes in people with haemophilia A [ID6400]

Issue date: March 2026

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • UK Haemophilia Centre Doctors' Organisation <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • Swedish Orphan Biovitrum (efanesoctocog alfa, factor VIII: efmoroctocog alfa) • Takeda (factor VIII: octocog alfa, susoctocog alfa) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Haematology • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.